X @Bloomberg
Novo NordiskNovo Nordisk(US:NVO) Bloomberg·2026-02-06 15:10

Novo Nordisk’s patents on semaglutide, the active ingredient in Ozempic, are starting to expire. On the Big Take podcast, @davidgura talks to @naomikresge and @AmberTongPW about how the company is navigating a dire 2026 sales projection https://t.co/vFQ40vZGYb ...